Phase 1 clinical trial data indicate igc's thc-based investigational new drug may reduce symptoms of dementia in alzheimer's patients

Potomac, md.--(business wire)-- #alzheimers--igc phase 1 clinical trial data indicate igc's thc-based investigational new drug may reduce symptoms of dementia in alzheimer's patients.

IGC Ratings Summary

IGC Quant Ranking